Login to Your Account



Keryx anemia drug hits endpoints in pivotal phase III trial

By Michael Fitzhugh
Staff Writer

Tuesday, March 29, 2016

Top-line data showing that ferric citrate, sold by Keryx Biopharmaceuticals Inc., can help certain patients with chronic kidney disease better deal with iron deficiency anemia positioned the company to seek an expanded label for the drug later this year.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription